Drug Search Results
More Filters [+]

AMG-256

Alternative Names: amg-256, amg 256, amg256
Latest Update: 2023-09-25
Latest Update Note: Clinical Trial Update

Product Description

AMG 256 (anti-PD-1 x IL21 mutein) is a targeted IL-21 receptor agonist designed to selectively turn on the Interleukin 21 (IL-21) pathway in programmed cell death-1 (PD-1) positive cells. It is being investigated for the treatment of solid tumors.

Mechanisms of Action: PD-1 Inhibitor,IL12 Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AMG-256

Countries in Clinic: Australia, Belgium, Spain, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT04362748

P1

Completed

Oncology Solid Tumor Unspecified

2023-09-21

48%

Recent News Events

Date

Type

Title